697 related articles for article (PubMed ID: 27132170)
1. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
3. Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment.
Giersch K; Perez-Gonzalez P; Hendricks L; Goldmann N; Kolbe J; Hermanussen L; Bockmann JH; Volz T; Volmari A; Allweiss L; Petersen J; Glebe D; Lütgehetmann M; Dandri M
JHEP Rep; 2023 Apr; 5(4):100673. PubMed ID: 36908749
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects of NTCP-inhibitor myrcludex B.
Cheng D; Han B; Zhang W; Wu W
J Viral Hepat; 2021 Jun; 28(6):852-858. PubMed ID: 33599010
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
6. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
7. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
8. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
9. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
10. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis delta and HIV infection.
Soriano V; Sherman KE; Barreiro P
AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
Blank A; Meier K; Urban S; Haefeli WE; Weiss J
Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
[TBL] [Abstract][Full Text] [Related]
14. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B.
Blank A; Markert C; Hohmann N; Carls A; Mikus G; Lehr T; Alexandrov A; Haag M; Schwab M; Urban S; Haefeli WE
J Hepatol; 2016 Sep; 65(3):483-9. PubMed ID: 27132172
[TBL] [Abstract][Full Text] [Related]
15. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insights into the inhibition of NTCP by myrcludex B.
Donkers JM; Appelman MD; van de Graaf SFJ
JHEP Rep; 2019 Oct; 1(4):278-285. PubMed ID: 32039379
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.
Giersch K; Bhadra OD; Volz T; Allweiss L; Riecken K; Fehse B; Lohse AW; Petersen J; Sureau C; Urban S; Dandri M; Lütgehetmann M
Gut; 2019 Jan; 68(1):150-157. PubMed ID: 29217749
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
20. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
